A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04438083 |
|
Recruitment Status :
Recruiting
First Posted : June 18, 2020
Last Update Posted : May 17, 2022
|
Sponsor:
CRISPR Therapeutics AG
Information provided by (Responsible Party):
CRISPR Therapeutics ( CRISPR Therapeutics AG )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | February 2027 |
| Estimated Study Completion Date : | April 2027 |